FDA Approves Opioid-Free Pain Medication With 'No Sign of Addiction' Treatment
The U.S. Food and Drug Administration has approved a new opioid-free pain medication called Journavx, marking a non-addictive alternative for patients suffering from chronic pain. The medication, made by Vertex, has shown no sign of addiction in clinical trials.
The US Food and Drug Administration has approved Journavx (suzetrigine), a new opioid-free pain medication that has shown no signs of addiction in clinical trials, marking a non-addictive alternative for patients with moderate to severe chronic pain. The medication, developed by Vertex, is expected to provide a safer treatment option for those struggling with opioid addiction. Journavx was approved after successful results from phase 3 clinical trials, demonstrating its effectiveness and safety in reducing pain without the risk of addiction. The approval makes suzetrigine a potential game-changer in the management of chronic pain.
